Here, the metabolic function of DCTPP1 was studied by using two different reverse genetics approaches, transient gene silencing and CRISPR/Cas9-based gene targeting, in two established mammalian cell models: breast cancer MCF-7 cells and the KBM-7-derived HAP1 cell line, respectively. This evidence concerns the gene DCTPP1 and breast carcinoma.